PLYMOUTH MEETING, PA--(Marketwire - November 29, 2010) - In advance of the first randomized, placebo-controlled clinical trial in the world of its type for Alzheimer's disease and other dementias, Quietmind Foundation (QMF), Plymouth Meeting, Pa., is honored to host two presentations by Gordon Dougal, M.D., a National Health Service physician, inventor, and dementia researcher from Durham, U.K. Dr. Dougal will discuss the application of 1072nm infrared light therapy in the treatment of dementia. The presentations will include the pioneering research findings from studies conducted by Dr. Dougal's colleagues at Durham University on the effects of this type of phototherapy on neuroprotection and beta amyloid plaque deposition and abeta42 oligomer levels.
Professional colleagues, caregivers, and family members of people struggling with neurodegenerative disorders are cordially invited. The free programs will take place on Sunday, December 12, from 4:00 p.m. to 5:30 p.m., and Monday, December 13, from 11:30 a.m. to 1:00 p.m., at the QMF offices, 521 Plymouth Rd., Suite 111, Plymouth Meeting, Pa., 19462. Light refreshments will be served.
Each program will begin with a brief scientific overview by Dr. Dougal directed toward professionals working in research and clinical care of people struggling with dementia. Marvin Berman, Ph.D., QMF's president, will then discuss the foundation's previous research in dementia and current clinical work. Following will be a demonstration of the 1072nm infrared light therapy and overview of parameters of the clinical trial to be conducted at the QMF offices.
For a fuller description of the upcoming clinical trial utilizing the 1072nm technology for the treatment of early stage dementia: http://clinicaltrials.gov/ct2/show/NCT01059877?term=1072&rank=3
About Quietmind Foundation
Quietmind Foundation, a 501(c)3 nonprofit founded in 2000, is an international center for cutting-edge research and consultation in the use of brainwave (EEG) biofeedback and related technologies. Its ongoing research agenda -- and the nondrug, noninvasive treatments offered through its affiliate, Quietmind Associates -- focuses on the spectrum of neurodegenerative disorders, including dementia, Parkinson's, ALS, and MS as well as traumatic brain injury, PTSD, and learning disabilities. Its goal is to integrate innovative technologies and evidence-based behavioral interventions into governmental, public health, and educational service delivery systems.
QMF's prior research on Alzheimer's disease was accepted for presentation at the July 2009 International Conference on Alzheimer's Disease (ICAD) in Vienna, Austria. This research demonstrated improvements in subjects' memory, executive function, and psychiatric symptoms, and a reduction in medications.
For further information and reservations for either presentation: 610-940-0488 or specialevents@quietmindfdn.org
Contact Information:
Press Contact:
For more information, contact:
Marvin H. Berman, Ph.D., CBT, BCN
Principal, Quietmind Associates
President, Quietmind Foundation
Psychotherapy, Assessment, Neurofeedback, Consultation,
and Applied Clinical Research
521 Plymouth Road, Suite 111
Plymouth Meeting PA 19462
T: 610-940-0488
F: 215-359-0630
E: